Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Maturing progenitor-like immunophenotypic cluster and megakaryocytic repopulating ability predict measurable residual disease in Acute Myeloid Leukemia

Olivia Wilkins, Jonathan Andreadakis, Alexander Shkembi, Amy Wu, John Basile, Anna Krzeczowska, Alexandra Thalberg, Linda Linderbeck, Nidia Zapata, Marci O'Driscoll, Suzane Silbert, Tiphaine Martin, Anne Renteria, Maher Albitar, Lacey Williams, Jason Salemi, Amy Alman, David Swoboda, Gustavo Rivero

Blood (2025) 146 (Supplement 1): 7049.

https://doi.org/10.1182/blood-2025-7049

Published: 2025

Journal Articles

Artificial intelligence‑driven virtual tumor board enhances precision care in Acute Myeloid Leukemia (AML)

David Swoboda, Jiasheng Wang, Thomas Kehoe, Gustavo Rivero, Aziz Nazha

Blood (2025) 146 (Supplement 1): 5176.

https://doi.org/10.1182/blood-2025-5176

Published: 2025

Journal Articles

Artificial intelligence system for delivering interactive and verifiable guideline-based clinical decision support in hematology

Jiasheng Wang, Kirti Arora, David Swoboda, Aziz Nazha

Blood (2025) 146 (Supplement 1): 2578.

https://doi.org/10.1182/blood-2025-2578

Published: 2025

Journal Articles

Artificial intelligence‑driven virtual tumor board enhances precision care in myelodysplastic syndromes (MDS)

David Swoboda, Amy DeZern, James England, Sangeetha Venugopal, Thomas Kehoe, Brandon Aubrey, Marco Gabriele Raddi, Angela Consagra, Jiasheng Wang, Gustavo Rivero, Maximilian Stahl, Amer Zeidan, Torsten Haferlach, Andrew Brunner, Rena Buckstein, Valeria Santini, Matteo Della Porta, Mikkael Sekeres, Aziz Nazha

Blood (2025) 146 (Supplement 1): 7363.

https://doi.org/10.1182/blood-2025-7363

Published: 2025

Journal Articles

Implementation of an innovative hospital at home program for patients with hematalogic malignancies

Nikesh Shah, Joanna Barris, Colleen Mcintosh, Peter Chang, Corinne Shamehdi, Daniel Kerr, Megan Melody, Ivan Borrello, Eduardo Sotomayor, David Swoboda

Blood (2025) 146 (Supplement 1): 520.

https://doi.org/10.1182/blood-2025-520

Published: 2025

Journal Articles

Developing transcriptomic signature for IDH1 and IDH2 acute leukemia and the demonstration of high prevalence of these signatures in mutation-negative leukemia

Maher Albitar, Hong Zhang, Gustavo Rivero, David Swoboda, Sally Agersborg, Adam Albitar, Ahmad Charifa, Andrew Ip, Andre Goy, Andrew Pecora, David Siegel, Kelly West Fitzpatrick, Katherine Linder, Jamie Koprivnikar, James McCloskey

Blood (2025) 146 (Supplement 1): 5251.

https://doi.org/10.1182/blood-2025-5251

Published: 2025

Journal Articles

Integrative clinical and molecular analysis of outcome in elderly African ancestry Acute Myeloid Leukemia

Blood (2025) 146 (Supplement 1): 1733.

https://doi.org/10.1182/blood-2025-1733

Published: 2025

Journal Articles

Oral azacitidine maintenance improved survival for t-AML or AML-MR patients in first remission after CPX-351 and not eligible to HSCT

Caroline Fileni, David Swoboda, Alexander Coltoff, Najla Al Ali, Rami Komrokji, Onyee Chan, Geoffrey Uy, Sarah Bertoli, Alessandro Isidori, Lenaig Le Clech, Mael Heiblig, Ludovic Gabellier, Patrick Lawrence, Lydia Kretschmer, Christoph Röllig, Jeffrey Lancet, Andrew Wei, David Sallman, Thomas Cluzeau

Blood (2025) 146 (Supplement 1): 3441.

https://doi.org/10.1182/blood-2025-3441

Published: 2025

Journal Articles

Phase 1 study of revumenib in combination with intensive chemotherapy (IC) in patients (Pts) with newly diagnosed (ND) Acute Myeloid Leukemia (AML) harboring genetic alterations in KMT2A, NPM1, or NUP98: SNDX-5613-0708

Ibrahim Aldoss, Carl Shultz, Bradley Hunter, David Swoboda, Pau Montesinos, Sarit Assouline, Shaun Fleming, Carolyn Grove, Andre Schuh, David Taussig, Karla Malloy, Enoch Cobbina, Jingshan Zhang, Mila Ayash-Rashkovsky, Jessica Clement, Eytan Stein, John DiPersio

Blood (2025) 146 (Supplement 1): 3425.

https://doi.org/10.1182/blood-2025-3425

Published: 2025

Journal Articles

Real-world validation of the molecular prognostic risk signature in acute myeloid leukemia treated with hypomethylating agents plus BCL-2 inhibitor.

Jonathan Andreadakis, Olivia Wilkins, Alexander Shkembi, Amy Wu, John Basile, Anna Krzeczowska, Alexandra Thalberg, Linda Linderbeck, Nidia Zapata, Suzane Silbert, Marci O'Driscoll, Anne Renteria, Maher Albitar, Lacey Williams, Jason Salemi, Amy Alman, Tiphaine Martin, David Swoboda, Gustavo Rivero

Blood (2025) 146 (Supplement 1): 3413.

https://doi.org/10.1182/blood-2025-3413

Published: 2025

Journal Articles

Evaluating large language models in real-world hematologic clinical decision-making: Performance, limitations, and clinical implications

Blood (2025) 146 (Supplement 1): 4349.

https://doi.org/10.1182/blood-2025-4349

Published: 2025

Journal Articles

Developing artificial intelligence-based transcriptomic signature for selecting patients with HOXA-MEIS1 pathway abnormalities for the treatment with menin inhibitors

Blood (2025) 146 (Supplement 1): 3471.

https://doi.org/10.1182/blood-2025-3471

Published: 2025

Journal Articles

Real world comparison of commercial CAR T-cell constructs for the treatment of LBCL

Blood (2025) 146 (Supplement 1): 781.

https://doi.org/10.1182/blood-2025-781

Published: 2025

Journal Articles

Glucose-6-phosphatase dehydrogenase [G6PD] serum level predicts acute monocytic leukemia differentiation.

Alexander Shkembi, Jonathan Andreadakis, Olivia Wilkins, Amy Wu, John Basile, Anne Renteria, Anna Krzeczowska, David Swoboda, Alexandra Thalberg, Linda Linderbeck, Nidia Zapata, Maher Albitar, Lacey Williams, Gustavo Rivero

Blood (2025) 146 (Supplement 1): 6902.

https://doi.org/10.1182/blood-2025-6902

Published: 2025

Journal Articles

Outcome with Hypomethylating Agent and Venetoclax Combination in Patients with Chronic Myelomonocytic Leukemia

Somedeb Ball, Akriti G Jain, Luis E. E. Aguirre, Najla Al Ali, Yumeng Zhang, Onyee Chan, Andrew T. Kuykendall, Kendra Sweet, Jeffrey E. Lancet, Eric Padron, David Swoboda, Rami S. Komrokji, David A. Sallman

Blood (2021) 138 (Supplement 1): 4138.

https://doi.org/10.1182/blood-2021-153681

Published: 2021

Journal Articles

Validation of the international working group proposal for SF3B1 mutant myelodysplastic syndromes

Rami Komrokji, Virginia Volpe, Onyee Chan, Najla Al Ali, David Swoboda, Andrew Kuykendall, Eric Padron, David A. Sallman

Blood (2021) 138 (11): 989–992.

https://doi.org/10.1182/blood.2021010831

Published: 2021

Journal Articles

Management of Catastrophic Antiphosphopholipid Syndrome with Eculizumab

Ami Chitalia, MD, David Swoboda, MD, Catherine Broome, MD

Blood (2016) 128 (22): 2603.

https://doi.org/10.1182/blood.V128.22.2603.2603

Published: 2016

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Maturing progenitor-like immunophenotypic cluster and megakaryocytic repopulating ability predict measurable residual disease in Acute Myeloid Leukemia

Artificial intelligence‑driven virtual tumor board enhances precision care in Acute Myeloid Leukemia (AML)

Artificial intelligence system for delivering interactive and verifiable guideline-based clinical decision support in hematology

Artificial intelligence‑driven virtual tumor board enhances precision care in myelodysplastic syndromes (MDS)

Implementation of an innovative hospital at home program for patients with hematalogic malignancies

Developing transcriptomic signature for IDH1 and IDH2 acute leukemia and the demonstration of high prevalence of these signatures in mutation-negative leukemia

Integrative clinical and molecular analysis of outcome in elderly African ancestry Acute Myeloid Leukemia

Oral azacitidine maintenance improved survival for t-AML or AML-MR patients in first remission after CPX-351 and not eligible to HSCT

Phase 1 study of revumenib in combination with intensive chemotherapy (IC) in patients (Pts) with newly diagnosed (ND) Acute Myeloid Leukemia (AML) harboring genetic alterations in KMT2A, NPM1, or NUP98: SNDX-5613-0708

Real-world validation of the molecular prognostic risk signature in acute myeloid leukemia treated with hypomethylating agents plus BCL-2 inhibitor.

Evaluating large language models in real-world hematologic clinical decision-making: Performance, limitations, and clinical implications

Developing artificial intelligence-based transcriptomic signature for selecting patients with HOXA-MEIS1 pathway abnormalities for the treatment with menin inhibitors

Real world comparison of commercial CAR T-cell constructs for the treatment of LBCL

Glucose-6-phosphatase dehydrogenase [G6PD] serum level predicts acute monocytic leukemia differentiation.

Outcome with Hypomethylating Agent and Venetoclax Combination in Patients with Chronic Myelomonocytic Leukemia

Validation of the international working group proposal for SF3B1 mutant myelodysplastic syndromes

Management of Catastrophic Antiphosphopholipid Syndrome with Eculizumab

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only